The live attenuated herpes zoster vaccine (ZVL) is recommended for immunocompetent adults 60 years or older, but the efficacy wanes with age and over time. A new adjuvanted herpes zoster subunit vaccine (HZ/su) has higher efficacy but might be more expensive. The choice of vaccines depends on their relative values.
I n 2006, the US Food and Drug Administration approved the live attenuated herpes zoster vaccine (ZVL) for prevention of postherpetic neuralgia (PHN). In randomized controlled trials (RCTs), ZVL reduced the incidence of PHN among people 60 years or older, and the Advisory Committee on Immunization Practices (ACIP) recommended vaccination in this age group. [1] [2] [3] [4] However, ZVL does not prevent all herpes zoster (HZ), particularly among the elderly. Moreover, the efficacy wanes completely after approximately 10 years. 1 To address these shortcomings, an adjuvanted HZ subunit vaccine (HZ/su) was recently developed. In RCTs, HZ/su reduced HZ incidence by 97% among people 50 years or older and was highly effective even after age 70 years. 5 The HZ/su is expected to be approved by the Food and Drug Administration soon, but widespread acceptance and coverage by insurance plans will require a recommendation from the ACIP, which must decide whether to prefer HZ/su over ZVL. One important issue will be cost-effectiveness. In June 2017, the ACIP met to examine the costeffectiveness of the 2 vaccines. They considered one model from GlaxoSmithKline (GSK), which manufactures HZ/su, and another model developed by Merck, which manufactures ZVL. 6 Both found HZ/su to be cost saving relative to ZVL, and the incremental cost-effectiveness ratios (ICERs) of HZ/su compared with no vaccination ranged from $12 000 per qualityadjusted life-year (QALY) for the GSK model to $74 000 per QALY for the Merck model. The range was influenced by assumptions of the modelers, who were employed by the competing manufacturers.
Once HZ/su is approved, physicians and patients will have to choose between the vaccines. The HZ/su appears to be more effective, especially among elderly patients, 5 and is likely to be more expensive. The HZ/su also requires 2 doses, a potential barrier to vaccination, which would affect the cost and the efficacy. To help decision makers, including the ACIP, payers, physicians, and patients, to choose the vaccine that offers the best value, we compared the cost-effectiveness of HZ/su with that of ZVL using an independent model with no pharmaceutical funding.
Methods

Study Design
We modified a validated Markov decision model [7] [8] [9] (eFigure 1 in the Supplement) to incorporate HZ/su and compare the costeffectiveness of the following 3 strategies: (1) no vaccination, (2) vaccination with ZVL, and (3) vaccination with HZ/su. The ZVL strategy included 1 dose, and the HZ/su strategy included 2 doses administered 2 months apart. We did not consider booster strategies because the ACIP does not currently recommend them. Because the cost-effectiveness of ZVL varies by vaccination age, we conducted analyses separately for 60-year-olds, 70-year-olds, and 80-year-olds. After vaccination, patients are followed up in 1-year Markov cycles. Each year, they may experience HZ and attendant complications (PHN, monocular blindness, monaural deafness, and hospitalization), recovery, or death, before ending in a mutually exclusive health state for the next cycle. The model terminates once everyone dies or reaches age 120 years. This study was modeled using data extracted from the literature, with no participant data involved. Therefore, institutional review board approval was not needed.
Compared with unvaccinated patients, vaccinated counterparts experience lower disease incidence and complication rates in proportion to each vaccine's efficacy. The model inputs were drawn from the US medical literature. The search was updated from a previous study. 9 We searched PubMed through January 2015, with search terms such as incidence, herpes zoster complications, prevalence of post-herpetic neuralgia, utility, and cost of herpes zoster relevant to each model input. The study dates were July 1 to 31, 2017. Outputs included cost and QALYs. The ICER was calculated as incremental costs divided by incremental QALYs between adjacent strategies after removing dominated strategies. Because there is no standard willingness-to-pay (WTP) threshold for cost-effectiveness in the United States, we chose $50 000 per QALY as the decision threshold and explored thresholds up to $100 000 per QALY. We conducted the study from the societal perspective, including direct medical costs and productivity losses. Costs were adjusted for inflation using the Consumer Price Index for Medical Care 10 and expressed in 2016 US dollars. The costs and QALYs were discounted at 3% per year. Analyses were performed using a computer program (TreeAge Pro 2017; TreeAge Software).
Model Inputs and Assumptions
Base-case point estimates and ranges for sensitivity analyses were recorded. 1,2,4-6,9,11-27 These are listed in Table 1 .Datawere derived from studies of fewer than 100 patients to more than 30 000 patients depending on the variable assessed. episodes. 28 Age-specific complication rates and background mortality were drawn from our previous model.
7,8
Vaccine-Related Parameters The efficacy of ZVL was modeled from the Shingles Prevention Study, the Short-Term Persistence Substudy, and the Long-Term Persistence Substudy. We used different functions to capture the long-term efficacy of ZVL against HZ incidence, PHN incidence, and burden of illness (BOI) using the following respective equations: y = 0.6478 − (0.0544 × year), y = 1.218 − (0.1 × year), and y =0 . 708 3− (0.0437 × year). We developed an equation to interrelate the efficacy against HZ incidence and the additional efficacy against PHN and BOI. The efficacy was further adjusted for vaccination age.
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The efficacy of HZ/su was reported in 2 RCTs. 5, 18 Apart from the efficacy against HZ incidence, HZ/su had no additional efficacy against PHN incidence or BOI. Therefore, we used a single efficacy function. The efficacy was higher at age 60 to 69 years compared with 70 years or older. 5, 18 The efficacy declined over 4 years, 18 with a slope of −3.6% per year, which did not differ significantly from the efficacy decline for ZVL of −5.4% per year; moreover, the wide 95% CI for HZ/su (−10.7% to 3.4%) completely encompassed the 95% CI for ZVL (−7.2% to −3.7%). Therefore, we assumed that initial efficacy differed by vaccination age and would decline at a rate identical to that of ZVL. The efficacy functions for HZ/su were y = 1.049 − (0.0544 × year) (age 60-69 years) and y = 1.008 − (0.0544 × year) (age ≥70 years). Therefore, the duration of HZ/su efficacy (the period that the efficacy exceeded 0%) was 19.3 years for vaccination at age 60 to 69 years and 18.5 years for vaccination at 70 years or older. Different durations were examined in sensitivity analyses.
The HZ/su requires 2 doses. In practice, some people will receive only 1 dose. Absent published data, we based singledose efficacy on manufacturer's information presented at the ACIP meeting. 6 Because there are no data, to date, on the waning rate of single-dose HZ/su, we assumed that the efficacy waned twice as fast for single-dose HZ/su as for 2 doses. All assumptions were evaluated in sensitivity analyses. The eAppendix in the Supplement describes the derivation of all efficacy functions. Although 95% of RCT participants received both doses of HZ/su, the proportion of persons who complete the series in practice will likely be smaller. Based on the adult hepatitis A vaccine series, which also contains 2 injections, we assumed 56.2% adherence.
19
Quality-Adjusted Life-years The utility estimates have been described previously. 8, 9 Local and grade 3 reactions were estimated to last one day, with utility equal to mild and severe pain, respectively. Utility of PHN beyond 6 months was calculated, assuming that 77% of patients have mild pain and 23% of patients have severe pain.
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Serious reactions were estimated to require 3 days in the hospital (the mean length of stay for a drug allergy), 16 with a utility of zero. Because the frequencies of vaccine reactions after the first and second doses were the same, we assumed the probabilities of vaccine reactions for 1 dose to be half of 2 doses. 5 We adjusted all utilities for age.
29
Costs Cost of ZVL was based on the private sector price of the Centers for Disease Control and Prevention. 24 Because HZ/su
is not yet licensed, we assumed a base-case price of $280 for a 2-dose regimen and varied it in sensitivity analysis. This as- b For the model inputs with age-specific values, the distribution was first defined for the lowest age group, which was considered as the reference. Distributions for remaining age groups were determined by multiplying relative likelihood ratios among these ages and the reference age by the reference distribution. Because the value was drawn randomly from the distribution in PSA, this definition of distributions ensured that the probabilistic values of different age groups had the appropriate relative magnitudes compared with one another as when they were deterministic. c Although the vaccine price is variable, it is determined by the manufacturer and not uncertain. Therefore, we did not define a probabilistic distribution for the vaccine price. However, we ran a number of PSAs at various HZ/su prices to show the variation of the probability of being cost-effective of each strategy by the vaccine price.
d This time loss was multiplied by the age-specific wage rate and the percentage of labor participation, resulting in an actual productivity loss due to vaccination with the second dose of $30, $9, and $4 per dose for people aged 60, 70, and 80 years, respectively.
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JAMA Internal Medicine February 2018 Volume 178, Number 2 (Reprinted) jamainternalmedicine.com sumption came from the GSK model as presented at the ACIP meeting. 6 Administration cost was set at Medicare's national reimbursement rate. 25 We assumed that the first dose of either vaccine was administered during a wellness visit and incurred no travel or productivity costs, 30 but the second HZ/su dose included these costs. We estimated travel cost equal to a round-trip bus ticket in Cleveland, Ohio, and productivity cost equal to 2 hours of time loss. 30-32 Productivity loss due to HZ was based on a US study, 33 adjusted for age-specific wage rate 23,34 and workforce participation. 35 Local reactions were assumed not to incur costs, whereas grade 3 reactions resulted in 1 lost workday. Cost of serious reactions was assumed to equal that of other allergic reactions requiring hospitalization. 16 Other costs were drawn from a previous study, 9 inflated to 2016 US dollars. We estimated length of stay and hospitalization costs from the 2014 Healthcare Cost and Utilization Project.
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Sensitivity Analysis
Deterministic Sensitivity Analysis We conducted 1-way sensitivity analyses to examine the association of input variables with cost-effectiveness. In addition, we explored values outside the ranges in Table 1 for prices of HZ/su, the waning rate and initial efficacy of a single HZ/su dose, and the adherence rate because these had the least data to support our estimates. We also tried excluding productivity loss. In 2-way sensitivity analysis, we examined the joint effect of price, the adherence rate of 2 HZ/su doses, initial efficacy, and the waning rate of 1 dose and 2 doses of HZ/su and ZVL. Finally, we conducted a 3-way analysis in which we varied the adherence rate, the waning rate, and the efficacy of 1 dose of HZ/su at the same time.
Probabilistic Sensitivity Analysis
We performed 10 000 iterations of Monte Carlo simulation to assess the effect of varying all model inputs simultaneously. Findings were presented as the cost-effectiveness acceptability curve, showing the probability of each strategy being costeffective over a range of WTP values, assuming an HZ/su price of $280 per series. We also performed probabilistic sensitivity analysis for 10 different HZ/su prices within the range of $150 to $600 per series ($75-$300 per dose) and plotted the percentage of iterations that each strategy had an ICER not exceeding $50 000 per QALY as a function of HZ/su price. Table 2 lists the costs and QALYs gained for each strategy. At all ages, no vaccination was always the least expensive and least effective, while HZ/su was always the most effective and less expensive than ZVL (ie, ZVL was dominated). The HZ/su was highly cost-effective compared with no vaccination, with an ICER below $50 000 per QALY at all ages.
Results
Base-Case Analysis
Sensitivity Analysis
One-Way Sensitivity Analysis Figure 1 shows the model inputs that caused the ICER of HZ/su compared with no vaccination to change by at least 10% for people vaccinated at age 60 years. The price and efficacy waning rate of 2 doses of HZ/su and the probability of PHN 12 months or longer were the 3 most important factors. Compared with no vaccination, HZ/su would be cost saving up to a price of $160 ($80 per dose).
Two-Way Sensitivity Analysis
Under all circumstances, HZ/su was always more effective than ZVL. The cost-effectiveness of HZ/su was sensitive to the price of HZ/su but insensitive to the price of ZVL. At the current price of ZVL ($213 per dose), HZ/su would be less costly than ZVL up to a price of $350 per series and cost-effective (compared with no vaccination) up to a price of $359 per series, assuming a WTP threshold of $50 000 per QALY (Figure 2A) . Conversely, at the proposed price of $280 per series, the price of ZVL would have to fall below $113 or below $68 to make HZ/su not cost-effective at $50 000 per QALY and $100 000 per QALY, respectively. Alternatively, if GSK increased the price of HZ/su by 50%, ZVL would become cost-effective if it cost less than $175 per dose. The cost-effectiveness of HZ/su was insensitive to the waning rate of either vaccine ( Figure 2B ). Conversely, results were more sensitive to the joint variations of the adherence and the waning rate. At base-case adherence (56.2%), HZ/su would be cost-effective regardless of the waning rate ( Figure 2C ) or initial efficacy of a single dose (eFigure 2 in the Supplement). However, when the adherence was less than 37.6%, HZ/su would not be cost-effective if the waning rate was greater than 10.9% per year or initial efficacy was less than 72.8%.
Three-Way Sensitivity Analysis
If the adherence to the second dose of HZ/su was greater than 56.8%, results were insensitive to the combined variation of the efficacy and the waning rate of single-dose HZ/su (eFigure 2 in the Supplement). However, at adherence rates below 40%, most combinations of faster waning rate and lower initial efficacy made HZ/su not cost-effective at either threshold. Vaccination with ZVL was never cost-effective at age 60 years.
Probabilistic Sensitivity Analysis Figure 3 shows the probability of each strategy being costeffective at various WTP thresholds. At a price of $280 per series, HZ/su had between 73% and 91% probability of being cost-effective at $50 000 per QALY and between 78% and 93% probability of being cost-effective at $100 000 per QALY, depending on vaccination age. In contrast, at age 60 years, ZVL had less than 5% chance of being cost-effective at either threshold. Additional sensitivity analyses are described in the eAppendix (including eFigures 3-8) in the Supplement.
Discussion
In this modeling study based on RCT data, we found that the new HZ/su was highly cost-effective compared with no vaccination for people 60 years or older. At a proposed price of $280 per series, HZ/su was both more effective and less expensive than the current ZVL at all ages. The finding was robust in sensitivity analysis. Across conceivable ranges of the efficacy duration, vaccine price, and probability of having PHN 12 months or longer, HZ/su was never more expensive than ZVL. Therefore, all discussion of the costeffectiveness is limited to comparison of HZ/su with no vaccination. In the base case, HZ/su cost less than $50 000 per QALY at all ages. In one-way sensitivity analysis, HZ/su sometimes had an ICER greater than $50 000 per QALY but never greater than $100 000 per QALY, unless the price exceeded $465 per series. What made the vaccine so costeffective was its high efficacy, which is initially at least 90% even among people 70 years or older, and this improvement could command a substantial premium over ZVL. Alternatively, if HZ/su cost less than $160 per series, it would actually save money compared with not vaccinating. At the June 2017 meeting, most of the ACIP work group leaned toward stating a preference for HZ/su over ZVL, which could allow for monopoly pricing. 36 To understand how this might affect price and ultimately cost-effectiveness, the case of ZVL is instructive. Original estimates of the costeffectiveness of ZVL ranged from $27 000 to $112 000 per QALY, which the ACIP determined was at the high end of the accept- the June 2017 ACIP meeting, both models presented found that the cost-effectiveness of ZVL now exceeds $120 000 per QALY, which is likely no longer in the acceptable range. If HZ/su was to rise at a similar rate, reductions in the price of ZVL could make it competitive. For that reason, it is important that the ACIP make its preferred recommendation conditional on maintaining the price, with a commitment to revisit the decision periodically.
In addition to maintaining competition, the ACIP working group identified several reasons not to express a preference for HZ/su. 36 There was concern that the 2-dose regimen would create another barrier to vaccination. Our model is reassuring in this regard. Because a single dose appears to offer high levels of protection (90% for 60-year-olds), HZ/su was the cost-effective option even if only 5% of patients received 2 doses. One caveat is that the efficacy estimate for a single dose was based on unpublished data provided by the manufacturer. GlaxoSmithKline performed post hoc analyses without a priori sample size calculations. These included data from the 2-month window between doses and from the 5% of individuals who did not receive the second dose. This represents approximately 29 311 patients but with a mean follow-up of less than 90 days. The 95% CIs were wide, especially for patients 70 years or older. If the efficacy is lower than expected, the adherence will need to be high to maintain cost-effectiveness: for example, if the efficacy of the first dose in patients at age 60 years was only 62% (the lower end of the 95% CI), the adherence to the second dose would need to exceed 47% for HZ/su to be costeffective at $50 000 per QALY. Future studies should examine the effectiveness and the waning rate of a single dose even as physicians should strongly encourage patients to complete the series. If HZ/su is preferred, there will be more grade 3 local reactions. Even so, the cost of HZ is so high that reactions had little effect on the cost-effectiveness of HZ/su. Last, relying on one manufacturer, the supply of Hz/su would be less assured. This is a legitimate concern; however, unlike the case with influenza, an interruption in vaccine supply to prevent HZ would not constitute a public health crisis. If the ACIP expresses no preference for HZ/su over ZVL, there will be many cases of avoidable HZ and PHN among vaccinated patients who could have received a more effective vaccine. Moreover, physicians, patients, or insurers may be tempted to choose the less expensive option, not realizing how much less effective it is. In that case, independent analyses, such as this one, will provide important information for relevant stakeholders. Because our study showed that ZVL could be cost-effective compared with HZ/su if Merck lowered the price substantially, we think that patients and insurers would benefit from the competition between 2 vaccines. One-way analysis also demonstrated that most uncertainties around the efficacy duration, serious reactions, and adherence rate would not make HZ/su less cost-effective than ZVL. Future studies to better define these values would provide more precise ICER estimates but would be unlikely to change our conclusions.
Limitations
Our study has several limitations. First, the long-term efficacy of HZ/su is unknown but did not appear to be an important determinant in sensitivity analyses. Second, the efficacy and duration for a single dose of HZ/su are unknown, as is the adherence to a second dose. We based our efficacy estimates on data from the ACIP June 2017 meeting 6 and made assumptions about vaccine duration.
The adherence rate was extrapolated from that of hepatitis A vaccine, which is rarely administered in the elderly. Because sensitivity analysis showed that combinations of these could potentially be important determinants, welldesigned studies should assess them. Third, we did not model the possibility of a ZVL booster, although it might be relevant given ZVL's limited efficacy duration. Fourth, some cost estimates were based on studies from the 1990s, inflated to current US dollars.
Conclusions
At a projected price of $280 per series, HZ/su was both more effective and less expensive than ZVL for adults 60 years or older. These findings were insensitive to most model inputs, particularly those about which there is considerable uncertainty, so long as the adherence to the second dose exceeds 50%. We made reasonable assumptions about the vaccine's efficacy duration and price, but our results would change if the vaccine price was to rise markedly in the future, if a single dose is much less effective than GSK reported, or if the adherence to the second dose is extremely low. Because of its superior efficacy, HZ/su was cost saving compared with ZVL and costeffective compared with no vaccination in most scenarios and should be recommended by the ACIP. An ACIP recommendation stating a preference for HZ/su over ZVL could lead to future price increases, which would render the vaccine no longer cost-effective. Therefore, a recommendation linked to periodic reassessment of cost-effectiveness based on the vaccine price might help to mitigate the effect of the recommendation on vaccine affordability. 
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Herpes zoster (HZ) affects almost 1 in 3 adults in the United States during their lifetime. The disease often causes severe pain that may last for a few weeks, with substantial influence on individuals' quality of life, daily activities, and work. Some patients continue to experience debilitating pain for more than a year, a complication that is known as postherpetic neuralgia (PHN). Serious cases can involve the eyes and central nervous system disease.
The HZ incidence increases sharply with age. For example, the incidence is 4.6 cases per 1000 person-years in those who are aged 50 to 59 years, and the rate increases to 10.3 cases per 1000 person-years in those who are 80 years or older. In addition, several observational studies demonstrate an upward trend in age-specific incidence of HZ. 1 The underlying cause of the upward trend is debated. 5 and the Long-Term Persistence Substudy (LTPS) 6 that followed up SPS participants, suggested substantially faster decline in efficacy rates than previously thought. Therefore, maintaining the protective effect against HZ required using a booster vaccine that could substantially change the initial cost-effectiveness estimates. Second, given that the incidence of HZ and vaccine efficacy varied by age, the economic evaluations were sensitive to age at vaccination, and the optimal age for vaccination was debated. 
METHODS
Long-term efficacy of the live attenuated herpes zoster vaccine (ZVL)
The Shingles Prevention Study was a randomized, placebo-controlled, double-blind trial involving 38,546 people aged ≥ 60 years. 1 The trial first reported efficacy data up to 4 years post-vaccination. A portion of participants were then followed in the Short-term Persistence Substudy 2 and Long-term Persistence Sub-study (LTPS) 3 up to 11 years post-vaccination. Three components of efficacy were reported: efficacy against HZ incidence, post-herpetic neuralgia (PHN) incidence, and burden of illness (BOI). Because HZ is necessary to experience either PHN or BOI, the measures are by definition interrelated, in particular because efficacy against PHN and BOI were greater than the efficacy against HZ, implying that even when the vaccine failed to prevent HZ, it still had some residual efficacy against these complications. BOI was a severity -by-duration measure which captured all pain and discomfort of HZ and was calculated as the area under the curve of HZ-related pain over time for up to 182 days after rash onset. Therefore, any reduction in BOI incorporated the vaccine's impact on HZ incidence and on the severity of pain among vaccinated HZ cases in the first 6 months after disease onset. Efficacy against PHN incidence included the vaccine's impact on HZ incidence leading to fewer HZ cases and subsequently fewer PHN cases and on PHN incidence among vaccinated persons who developed HZ. Therefore, we modeled long-term efficacy of the ZVL using three different efficacy functions. We first estimated the long-term efficacy against HZ incidence by year, using yearly efficacy data in the first 6 years and an aggregated efficacy for 7-11 years postvaccination . This efficacy was further adjusted for vaccination age difference. 4, 5 Efficacy against BOI was obtained by fitting a linear regression on the three aggregated data points reported for SPS, STPS and LTPS ( ). [1] [2] [3] Regarding PHN incidence, the LTPS also reported yearly efficacy but these estimates were not statistically significant. 3 Therefore, we assumed a stable efficacy for the first 5 years using the aggregated data and a declining function at year 6 ( ). The three efficacy components were then related to each other in a function to estimate the additional efficacies against BOI or PHN incidence among HZ cases. where x is efficacy against BOI (or PHN incidence) among HZ cases, Eff is the efficacy against BOI (or PHN incidence) and Eff HZ is the efficacy against HZ incidence as described above. For vaccinated patients, we applied the efficacy against HZ incidence first, i.e. the vaccine would make them less likely to develop HZ. However, because the efficacy against HZ was not 100%, vaccinated patients might still develop HZ, in which case the efficacy against BOI was applied to reduce the loss of quality-adjusted life years due to HZ. Finally, the vaccine would further reduce PHN incidence among these vaccinated HZ cases. The validation of these efficacy functions and graphs were presented in our previous study. 
Long-term efficacy of the adjuvanted subunit vaccine (HZ/su) Efficacy of 2 doses
We estimated the initial efficacy of HZ/su based on ZOE-50 and ZOE-70. 7, 8 These randomized controlled trials did not measure BOI, and the efficacy against PHN was actually lower than the efficacy against HZ incidence, meaning that HZ/su had no additional efficacy against PHN incidence among HZ cases who were vaccinated. In fact, patients who experienced HZ despite vaccination with HZ/su were more likely than average patients to experience PHN. However, the number of cases of PHN was so small that the confidence interval around this estimate was extremely wide, and it seems unlikely that the vaccine would increase the risk of PHN among breakthrough cases. Therefore, we use a single efficacy function to represent HZ/su efficacy against HZ incidence.
We chose to use the efficacy reported for the total cohort instead of the modified vaccinated cohort because the latter excluded patients not receiving the second dose and those experiencing HZ within 1 month after the second dose. We assumed the average efficacy for the first three years after vaccination was 94.1% (95% confidence interval (CI): 85.6-98.1) for patients aged 60-69 years and 89.9% (95% CI: 85.4-93.2) for patients aged ≥70 years because the mean follow-up time of ZOE-50 and ZOE-70 was 3.2 and 3.7 years, respectively. Yearly efficacy data was available for patients aged ≥70 years, and efficacy declined right after year 1. As we described in the text, the linear regression function fit on these values returned a slope or waning rate of -3.64% with 95% CI of (-10.68% -3.4%) which was not statistically significant. In addition, this 95% CI encompasses the 95% CI of the slope of the efficacy function for ZVL against HZ incidence. Therefore, we assumed that HZ/su had the same waning rate as the ZVL and used it to calculate the intercept of the efficacy function for HZ/su. The final efficacy functions for HZ/su were (age 60-69 years) and (age ≥70 years). eTable 1 presents the efficacy against HZ incidence of ZVL and HZ/su in the first 10 years post vaccination in the base-case.
Efficacy of 1 dose
HZ/su series includes 2 doses administered 2 months apart. In clinical practice, it is possible that patients might not get 2 doses, so efficacy estimate of a single HZ/su dose is necessary to calculate its effectiveness accurately. However, there have been no clinical studies conducted to assess the efficacy of a single dose. In an exploratory analysis using data from ZOE-50 and ZOE-70, the initial efficacy of 1 dose was 90% (95% CI: 62.1%-99%) in patients aged 60-69 years and 69.5% (24.9%-89.1%) in patients aged ≥70 years. This analysis included data for the whole study period from 5% of patients who did not complete 2 doses and for the observation window between dose 1 and 2 from 95% of patients who received both doses. The mean follow-up time was, therefore, <3 months. Due to lack of data, we conservatively assumed that the efficacy waning rate for 1 dose was twice as much as for 2 doses, yielding efficacy functions for a single HZ/su dose of (age 60-69 years) and (age ≥70 years)
RESULTs
One-way sensitivity analysis eTable 2 presents additional data on costs, QALY and ICERs of three strategies at different HZ/su prices among people vaccinated at 60 years. The higher the cost of HZ/su, the less cost-effective the HZ/su was. If the HZ/su price was double the base-case, the ICER of HZ/su compared to ZVL was more than $100,000/QALY.
In addition, compared to no vaccination, the ICER of HZ/su was $42,676/QALY when the waning rate of a single HZ/su dose was double the base-case, $36,834/QALY when adherence rate was half of base-case, $49,198/QALY when the initial efficacy of a single HZ/su dose was half the base-case, and $63,968/QALY when productivity loss was excluded. The model begins with a decision node representing the choice to vaccinate with one of the vaccines, or no vaccine. For ZVL and no vaccine options, the cohort then moves to a chance node of male or female depending on the sex distribution of general population corresponding to the age of vaccination. After that, the cohort enters the Markov node and starts at the "Healthy" state for the first cycle. For subsequent cycles, they move between Markov health states depending on transition probabilities until everyone arrives in the "Dead" state, at which point the model terminates. For the HZ/su option, the cohort can receive 1 or 2 doses of the vaccine. The events afterwards are similar to those in the ZVL option. 
